Baseline characteristics, comorbidities and clinical findings in pulmonary embolism patients, stratified according to the median MR-proANP concentration, and odds ratios for predicting MR-proANP ≥142 pmol·L−1
| All study patients | MR-proANP <142 pmol·L−1 | MR-proANP ≥142 pmol·L−1 | p-value | OR (95% CI) | p-value | |
| Patients n | 609 | 261 | 261 | |||
| Age years | 69 (56–77) | 57 (43–70) | 76 (69–82) | <0.001 | age ≥75 years: 8.86 (5.75–13.66) | <0.001 |
| Female sex | 323 (53.0) | 118/261 (45.2) | 155/261 (59.4) | 0.001 | 1.96 (1.32–2.91) | 0.001 |
| Comorbidities | ||||||
| Active cancer | 107/608 (17.6) | 45/261 (17.2) | 46/260 (17.7) | 0.892 | 1.07 (0.64–1.78) | 0.810 |
| Chronic pulmonary disease | 88/608 (14.4) | 32/261 (12.3) | 43/260 (16.5) | 0.165 | 1.32 (0.76–2.30) | 0.325 |
| Chronic heart failure | 88 (14.4) | 14/261 (5.4) | 57/261 (21.8) | <0.001 | 5.09 (2.56–10.15) | <0.001 |
| Atrial fibrillation | 64/603 (10.6) | 9/258 (3.5) | 45/260 (17.3) | <0.001 | 7.89 (3.02–20.62) | <0.001 |
| Coronary artery disease | 105 (17.2) | 22/261 (8.4) | 64/261 (24.5) | <0.001 | 3.23 (1.83–5.71) | <0.001 |
| Arterial hypertension | 370/609 (60.8) | 121/261 (46.4) | 196/2261 (75.1) | <0.001 | 3.54 (2.32–5.41) | <0.001 |
| Renal insufficiency | 187/601 (31.1) | 30/260 (11.5) | 128/261 (49.0) | <0.001 | 7.02 (4.16–11.82) | <0.001 |
| Symptoms on admission | ||||||
| Dyspnoea | 477/605 (78.8) | 199/261 (76.2) | 204/257 (79.4) | 0.392 | 1.10 (0.66–1.86) | 0.708 |
| Chest pain | 279/603 (46.3) | 139/261 (53.3) | 100/256 (39.1) | 0.001 | 0.58 (0.39–0.86) | 0.006 |
| Syncope | 96/607 (15.8) | 24/261 (9.2) | 56/259 (21.6) | <0.001 | 2.89 (1.53–5.44) | 0.001 |
| Tachycardia# | 214/589 (36.3) | 79/257 (30.7) | 107/247 (43.3) | 0.003 | 1.83 (1.21–2.78) | 0.004 |
| Hypoxia | 162/523 (31.0) | 45/220 (20.5) | 95/230 (41.3) | <0.001 | 2.54 (1.59–4.15) | <0.001 |
| Cardiogenic shock | 51/608 (8.4) | 12/261 (4.6) | 32/260 (12.3) | 0.002 | 5.71 (1.64–19.90) | 0.006 |
| Laboratory biomarkers | ||||||
| hsTnT ≥14 pg·mL−1 | 367/568 (64.6) | 101/257 (39.3) | 227/257 (88.3) | <0.001 | 9.33 (5.60–15.55) | <0.001 |
| NT-proBNP ≥600 pg·mL−1 | 286/554 (51.6) | 72/257 (28.0) | 197/260 (75.8) | <0.001 | 8.21 (5.23–12.89) | <0.001 |
| ESC 2019 algorithm | ||||||
| High risk | 53/608 (8.7) | 12/261 (4.6) | 34/260 (13.1) | 0.001 | 3.12 (1.58–6.18) | 0.001 |
| Intermediate–high risk | 160/608 (26.3) | 40/261 (15.3) | 101/260 (38.8) | <0.001 | 3.51 (2.31–5.34) | <0.001 |
| Intermediate–low risk | 295/608 (48.4) | 129/261 (49.4) | 118/260 (45.4) | 0.356 | 0.85 (0.60–1.20) | 0.356 |
| Low risk | 100/608 (16.4) | 80/261 (30.7) | 7/260 (2.7) | <0.001 | 0.06 (0.03–0.14) | <0.001 |
Continuous variables are presented as median (interquartile range), categorical variables are presented as absolute/total numbers (%). MR-proANP: mid-regional pro-atrial natriuretic peptide; hsTnT: high-sensitivity troponin T; NT-proBNP: N-terminal pro-B-type natriuretic peptide; ESC: European Society of Cardiology. #: heart rate ≥100 beats·min−1. Bold indicates p<0.05.